Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
To compare renal allograft rejection rates during the first year among high-immunological
risk recipients between patients who received either ATG or the anti-IL2R mAb daclizumab.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Lille
Collaborator:
Erasme University Hospital
Treatments:
Antilymphocyte Serum Daclizumab Immunoglobulin G Mycophenolate mofetil Thymoglobulin